source
- GSK to cut over 1,200 jobs at Belgian sites as $2.5 bn restructuring continuesGSK announced it will eliminate more than 1,200 positions across its Belgian facilities, following an earlier closure of a German vaccine plant that cut about 650 jobs. The reductions are part of…
- Ultragenyx sells second priority review voucher as Biomea shares tumble after oral GLP-1 dataUltragenyx Pharmaceutical, a commercial-stage rare disease company, completed its second sale of a priority review voucher this month. The voucher sale reflects the company's strategy of monetizin…